CUTTING EDGE APPROACHES to DRUG DESIGN

CUTTING EDGE APPROACHES
to DRUG DESIGN

March 13 2001, SSLT, London

Programme

10.00	Chairman: Dr Terry Hart* (Novartis)* Welcome and Introduction
10.05	Structural biology, genomics and drug discovery Professor Tom Blundell (University of Cambridge)
11.00	High throughput proteomics for novel target identification in drug discovery OGS Speaker
11.35	COFFEE
11.55	Virtual screening of virtual libraries; a strategy for efficient lead generation Dr Darren Green (GSK)
12.30	Structure assisted design of inhibitors of N-myristoyl transferase Dr Dave Brown (Pfizer)
1.05	LUNCH
	Chairman: Dr Darren Flower* (Jenner Institute)*
2.00	New approaches to lead optimisation: How good are we now and what comes next? Dr Iain Mclay (GSK)
2.35	Computational approaches to physical organic chemistry and the prediction of drug-like properties Dr Andy Davis (AstraZeneca)
3.10	TEA

3.30	Principles of molecular recognition in the ATP binding site of protein kinases. Application to the design of inhibitors Dr Pascal Furet (Novartis)
4.05	GPCR modelling in the design of neurokinin antagonists Dr Frank Blaney (GSK)
4.40	5HT1D/1B GPCR modelling and mutagenesis Dr Peter Hunt (Merck, Sharp and Dohme)
5.10	CLOSE